PD05-08 ELEVATED FM/a BLOOD TEST IN PATIENTS WITH INTERSTITIAL CYSTITIS / BLADDER PAIN SYNDROME

Abstract

You have accessJournal of UrologyCME1 Apr 2023PD05-08 ELEVATED FM/a BLOOD TEST IN PATIENTS WITH INTERSTITIAL CYSTITIS / BLADDER PAIN SYNDROME Claire Burton, Ashu Mohammad, Sean Berquist, and Amy Dobberfuhl Claire BurtonClaire Burton More articles by this author , Ashu MohammadAshu Mohammad More articles by this author , Sean BerquistSean Berquist More articles by this author , and Amy DobberfuhlAmy Dobberfuhl More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003229.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The FM/a test is a cytokine assay of in vitro stimulated peripheral blood mononuclear cells that has been previously validated for the diagnosis of fibromyalgia (FM). FM and Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS) share many common features, and cytokine abnormalities have been previously identified in both conditions. It has been hypothesized that the non-Hunner Lesion (HL) phenotype of IC/BPS may be more related to systemic pain syndromes and have overlap with FM. We hypothesized that patients with IC/BPS would also test positive on the FM/a test. METHODS: Men and women ≥18 years of age with a diagnosis of IC/BPS were included in the study. Patients were excluded if they were taking immunosuppressants or oral or inhaled steroids. All patients were prospectively enrolled and completed the blood test as well as the AUA-SS and the O’Leary-Sant Symptom and Problem Indices. Charts were reviewed for chronic overlapping pain conditions (COPCs) which include Irritable bowel syndrome, FM, chronic fatigue syndrome, migraine, and temporomandibular joint disorder as well as the prevalence of HL. RESULTS: A total of 15 patients enrolled in the study. 73% (11/15) of patients tested positive for FM/a with a score >50. Distribution of FM/a results is presented in Figure 1. One patient who tested negative reported being on Flonase and was excluded from further analysis. 13/14 had previously undergone cystoscopy for evaluation of HL. Demographic data is presented in Table 1. There was no difference in FM/a results among subjects with and without COPCs (70.8 vs 55.3, p=0.31) or HL vs Non-HL IC/BPS (65.2 vs 64.8, p=0.98). CONCLUSIONS: The FM/a test is highly positive in this small sample of patients with IC/BPS, the majority of whom do not carry a prior FM diagnosis. While the clinical utility of this test is uncertain, there may be potential to use this test to further phenotype patients with IC/BPS and/or clarify the diagnosis if in question. Further study of the sensitivity and specificity of the FM/a test in IC/BPS patients is warranted. Source of Funding: EpicGenetics paid for the laboratory fees and conducted the FM/a Test free of charge © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e151 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Claire Burton More articles by this author Ashu Mohammad More articles by this author Sean Berquist More articles by this author Amy Dobberfuhl More articles by this author Expand All Advertisement PDF downloadLoading ...